Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tiragolumab + atezolizumab + chemotherapy
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Tiragolumab + atezolizumab + chemotherapy is a combination regimen evaluated in cancer therapy, notably for lung cancers. **Tiragolumab** is a monoclonal antibody targeting TIGIT, an inhibitory immune checkpoint on T-cells and NK cells, aiming to enhance anti-tumor immune response[1][2][4]. **Atezolizumab (Tecentriq)** is a monoclonal antibody inhibiting PD-L1, which blocks the PD-1/PD-L1 pathway to reactivate T cells against tumors[1][2][4]. The **chemotherapy** component typically includes agents like carboplatin and etoposide, contributing direct cytotoxic effects against cancer cells[3][4][5]. This combination was investigated for extensive-stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCLC), with the goal of improving immune-mediated tumor control by dual checkpoint inhibition alongside standard cytotoxic chemotherapy[3][4][6].
- Other names
- tiragolumab + atezolizumab + chemotherapy
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)DNATIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on tiragolumab + atezolizumab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tiragolumab + atezolizumab + chemotherapy.